Korean J Pediatr Infect Dis.  2011 Dec;18(2):117-123.

The Change of IgG Antibody Titer to Measles, Mumps and Rubella According to Age

• Pang SJ
• Choi KM

Abstract

PURPOSE
We investigated the change of antibody titer to measles, mumps and rubella according to age after vaccination.
METHODS
The IgG antibody titers to measles, mumps and rubella were tested on the residual serum from patients aged 7-20 years old after routine laboratory testing in the hospital with informed consent from the parents.
RESULTS
Antibody to measles was present in 275 cases out of 408 cases with a positive rate of 67.4%, the mean IgG titer was 2.77+/-1.18 Index. Antibody to mumps was present in 112 cases out of 408 cases with a positive rate of 27.5%, the mean IgG titer was 2.08+/-1.29 Index. Antibody to rubella was present in 367 cases out of 408 cases with a positive rate of 90.0%, the mean IgG titer was 60.46+/-63.47 IU/mL.
CONCLUSION
It is important to maintain a high rate of vaccination coverage in order to prevent an outbreak of measles, mumps, or rubella. It is also important to stress the maintenance of vaccination records for further reference.

Keyword

Measles; Mumps; Rubella; IgG antibody

MeSH Terms

Aged
Humans
Immunoglobulin G
Informed Consent
Measles
Mumps
Rubella
Vaccination
Immunoglobulin G

Reference

1. Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep. 2009. 58:1321–1326.

2. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis. 2007. 13:12–17.

3. Atrasheuskaya AV, Blatun EM, Kulak MV, Atrasheuskaya A, Karpov IA, Rubin S, et al. Investigation of mumps vaccine failures in Minsk, Belarus, 2001-2003. Vaccine. 2007. 25:4651–4658.

4. Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis. 2007. 45:459–466.

5. Bloch AB, Orenstein WA, Ewing WM, Spain WH, Mallison GF, Herrmann KL, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics. 1985. 75:676–683.

6. Riley EC, Murphy G, Riley RL. Airborne spread of measles in a suburban elementary school. Am J Epidemiol. 1978. 107:421–432.

7. Bellanti JA, Sanga RL, Klutinis B, Brandt B, Artenstein MS. Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines. N Engl J Med. 1969. 280:628–633.

8. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J Pediatr. 1965. 66:471–488.

9. Krause PJ, Cherry JD, Carney JM, Naiditch MJ, O'Connor K. Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am J Dis Child. 1980. 134:567–571.

10. Gallagher MR, Welliver R, Yamanaka T, Eisenberg B, Sun M, Ogra PL. Cell-mediated immune responsiveness to measles. Its occurrence as a result of naturally acquired or vaccine-induced infection and in infants of immune mothers. Am J Dis Child. 1981. 135:48–51.

11. Pedersen IR, Mordhorst CH, Ewald T, von Magnus H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. Vaccine. 1986. 4:173–178.

12. Erdman DD, Heath JL, Watson JC, Markowitz LE, Bellini WJ. Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection. J Med Virol. 1993. 41:44–48.

13. Yoo JW, Sohn HE, Chung NE, Choi TY. Age related measles antibody levels after vaccination. Korean J Clin Pathol. 1999. 19:227–233.

14. Shin YK, Yoon JK, Choung JT, Tockgo YC. Changes of measles specific IgG after active immunization of measles in Korean children. J Korean Pediatr Soc. 1996. 39:788–796.

15. Parker AA, Staggs W, Dayan GH, Ortega-Sanchez IR, Rota PA, Lowe L, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med. 2006. 355:447–455.

16. Hethcote HW. Measles and rubella in the United States. Am J Epidemiol. 1983. 117:2–13.

17. King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J. 1991. 10:883–888.

18. Watson JC, Pearson JA, Markowitz LE, Baughman AL, Erdman DD, Bellini WJ, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics. 1996. 97:613–618.

19. Ramsay ME, Jin L, White J, Litton P, Cohen B, Brown D. The elimination of indigenous measles transmission in England and Wales. J Infect Dis. 2003. 187:Suppl 1. S198–S207.

20. Measles--United States, 1996, and the interruption of indigenous transmission. MMWR Morb Mortal Wkly Rep. 1997. 46:242–246.

21. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999. 77:3–14.

22. Oh SH, Yum DH, Kang JH, Sohn YM, Lee HJ, Pyun BY, et al. Distribution of Anti-Mumps IgM Antibody in Children Presumptively Diagnosed of Mumps. J Korean Pediatr Soc. 2001. 44:17–24.

23. Na BK, Go UY, Lee JY, Lee JS, Shin GC, Lee JY, et al. Seroepidemiology of mumps IgG antibody on primary school children in Kyonggi province, 1996 and 1999. Korean J Infect Dis. 2001. 33:157–164.

24. Shin YK, Cheon HW, Lee KH, Choung JT, Tockgo YC. Mumps and rubella-specific IgG levels of term pregnant women and their neonates. J Korean Pediatr Soc. 1998. 41:47–52.

25. Park YB, Jung EG, Moon KR. A measurement of mumps specific IgG & IgM antibody in the sera of mumps vaccinated healthy children. J Korean Pediatr Soc. 1996. 39:491–496.

26. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA. 2000. 284:2643–2647.

27. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 1995. 13:799–802.

28. Boulianne N, De Serres G, Ratnam S, Ward BJ, Joly JR, Duval B. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine. 1995. 13:1611–1616.

29. Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996. 15:687–692.

30. Lee SJ, Kim CH. Prevalence of Rubella Antibodies and Preventive Measures of Congenital Rubella Syndrome in Korea. J Korean Pediatr Soc. 1996. 39:151–165.